Stavropol', Stavropol, Russian Federation
LLC «AG «Aspect» (Veterinarian)
LLC «RDE «Astrapharm» (Leading veterinarian)
LLC «BioFeron» (Leading veterinarian)
employee
Russian Federation
LLC «RDE «Astrapharm» (Chief science specialist)
LLC «BioFeron» (Chief science specialist)
employee
Russian Federation
68.41
This article presents the results of the toxicological evaluation of a new generic drug for veterinary use Firocoxib-ASTRA® tablets, which is a complete analogue of the imported drug Previcox. The active ingredient of the drug firocoxib is a modern representative of the NSAID family of coxibs, a selective COX-2 inhibitor. Due to its high gastrointestinal safety profile, the drug is more preferable for dogs compared to other, less selective NSAIDs. Firocoxib-ASTRA® is indicated for dogs with osteoarthritis and osteoarthrosis, joint injuries, inflammatory processes of soft tissues and for postoperative pain control. Due to its high selectivity and low risk of adverse reactions, it can be used both for short-term relief of acute pain and for long-term control of chronic diseases of the musculoskeletal system. LD50 of the drug for rats is 2410±27.46 mg/kg, which, according to GOST 12.1.007-76, allows it to be classified as hazard class III – «Moderately hazardous substances». Based on the results of the subchronic oral toxicity assessment, it was found that the use of the drug for 42 days in all tested increased doses does not cause significant changes in the clinical condition and hematological parameters of experimental animals. No negative impact on the main physiological functions of the body was found, there are no pathomorphological changes, which confirms the good tolerability of the drug. Firocoxib-ASTRA® does not have allergenic properties detected in provocative skin, conjunctival and nasal tests, and does not cause mast cell degranulation beyond the normal range. Thus, the results of this study allow us to conclude that the new drug Firocoxib-ASTRA® tablets does not have toxic and allergenic properties, and is well tolerated by laboratory animals.
Firocoxib-ASTRA® tablets, firocoxib, LD50, acute oral toxicity, subchronic oral toxicity, allergenic properties, rats, guinea pigs, blood, hematology, biochemistry
1. Belen'kiy, M.L. Elementy kolichestvennoy ocenki farmakologicheskogo effekta / M.L. Belen'kiy. ‒ Leningrad: Gosudarstvennoe izdatel'stvo medicinskoy literatury, 1963. ‒ 151 s.
2. Danilevskaya, N.V. Nesteroidnye protivovospalitel'nye preparaty i ih ispol'zovanie v prakticheskoy veterinarii / N.V. Danilevskaya // Veterinar. ‒ 2000. ‒ № 4. ‒ S. 34-37.
3. Karateev, A.E. Chto luchshe dlya profilaktiki NPVP-gastropatii: koksiby ili kombinaciya «tradicionnyh» NPVP i gastroprotektora?/ A.E. Karateev // RMZh. ‒ 2013 . ‒ № 13. ‒ S. 673.
4. Kemel'man, E.L., Ocenka chastoty vozniknoveniya gastroenterologicheskih oslozhneniy pri naznachenii sobakam karprofena v kombinacii s omeprazolom / E.L. Kemel'man, K.S. Varenov, A.A. Arhipova // RVZh MDZh. – 2015. ‒ №1. ‒ S. 16-19.
5. Previkoks tabletki 57 mg i 227 mg Instrukciya po veterinarnomu primeneniyu lekarstvennogo preparata [Elektronnyy resurs]. – URL: https://galen.vetrf.ru/files/instruction/1b2e0703-a97b-46a9-b8dd-9899639215f6 (data obrascheniya 09.01.2025).
6. Prikaz Ministerstva sel'skogo hozyaystva RF №101 ot 06.03.2018 g. «Ob utverzhdenii Pravil provedeniya doklinicheskogo issledovaniya lekarstvennogo sredstva dlya veterinarnogo primeneniya, klinicheskogo issledovaniya lekarstvennogo preparata dlya veterinarnogo primeneniya, issledovaniya bioekvivalentnosti lekarstvennogo preparata dlya veterinarnogo primeneniya». Zaregistrirovan v Minyuste Rossii 05.06.2018 № 51296.
7. Rukovodstvo po provedeniyu doklinicheskih issledovaniy lekarstvennyh sredstv. Chast' pervaya / A.N. Mironov, N.D. Bunatyan i dr. – M.: Grif i K, 2012. – 944 s.
8. Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniyu novyh farmakologicheskih veschestv / Pod red. R. U. Habrieva. – M.: Medicina, 2005. – 832 s.
9. Cotnikov, V.V. Ispol'zovanie nesteroidnyh protivovospalitel'nyh preparatov (NSPVP) v veterinarnoy praktike / V.V. Sotnikov // Veterinarnyy Peterburg. ‒ 2011. ‒ №2. ‒ S. 33-35.
10. Firokoksib-ASTRA® tabletki Instrukciya po veterinarnomu primeneniyu lekarstvennogo preparata [Elektronnyy resurs]. – URL: https://galen.vetrf.ru/files/c6b589ad-ca70-48bc-81fc-58de1c3cb966 (data obrascheniya 09.01.2025).
11. Aithal, G.P. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity/ G.P. Aithal, C.P. Day // Clinics in Liver Disease. ‒ 2007. ‒No. 11. ‒ pp. 563-575.
12. Bergh, M.S. The coxib NSAIDs: potential clinical and pharmacological importance in veterinary medicine / M.S. Bergh, S.C. Budsberg // J Vet Intern Med. ‒ 2005. No. 19. ‒ pp. 633-43.
13. Bostrom, I.M. Effects of carprofen on renal function and results of serum biochemical and hematologic analyses in anesthetized dogs that had low blood pressure during anesthesia / I.M. Bostrom, G.C. Nyman, P.E. Lord, et al. // Am J Vet Res. ‒ 2002. ‒ No. 63. ‒ pp. 712-721.
14. Clark, T.P. The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors / T.P. Clark // Vet Clin North America Small Anim Pract. ‒ 2006. ‒ No. 36(5). ‒ pp. 1061-85.
15. Dassler, C.L. Canine hip dysplasia: diagnosis and nonsurgical treatment / CL. Dassler. In: Slatter D, editor. Textbook of small animal surgery. 3rd edition. Philadelphia: WB Saunders, 2002. ‒ pp. 2019-29.
16. Doig, P.A. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis / P.A. Doig, K.A. Purbrick, J.E. Hare, et al. // Can Vet J. ‒ 2000. ‒ No. 41. ‒ pp. 296-300.
17. Forsyth, S.F. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs / S.F. Forsyth // JSAP. ‒ 1998. ‒ Vol. 39. ‒ Iss. 9. ‒ pp. 421-424.
18. Fox, S.M. Non-Steroidal Anti-Inflammatory Drugs / S.M. Fox. In Chronic Pain in Small Animal Medicine. 1st ed. London: Manson Publishing Ltd, 2010. ‒ p. 138- 163.
19. Gruen, M.E. Pain Management Guidelines for Dogs and Cats / M.E. Gruen, B.D.X. Lascelles, E. Colleran, et al. // J Am Anim Hosp Assoc. ‒ 2022. ‒ No. 58(2). ‒ pp. 55-76. doihttps://doi.org/10.5326/JAAHA-MS-7292.
20. Gwaltney-Brant, S.M. Toxicology of pain medications / S.M. Gwaltney-Brant // Proceedings of the Central Veterinary Conference (CVC), Baltimore, MD, 2010.
21. Hanson, P.D. Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions / P.D. Hanson, K.C. Brooks, J. Case, M. Conzemius, W. Gordon, J. Schuessler, et al. // Vet Ther. ‒ 2006. ‒ No. 7(2). ‒ pp. 127-40.
22. Hazewinkel, H.A.,= Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs / H.A. Hazewinkel, W.E. van den Brom, L.F. Theyse, M. Pollmeier, P.D. Hanson // Res Vet Sci. ‒ 2008. ‒ No. 84(1). ‒ pp. 74-9.
23. Innes, J.F. Arthritis / J.F. Innes. In: Tobias KM, Johnston SA, editors. Veterinary surgery small animal. St Louis (MO): Elsevier Saunders, 2012. ‒ pp. 1078-111.
24. Johnston, S.A. Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis / S.A. Johnston, S.C. Budsberg // Vet Clin North Am Small Anim Pract. ‒ 1997. ‒ No. 27. ‒ pp. 841-862.
25. Jones, C.J. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats / C.J. Jones // J Am Vet Med Assoc. ‒ 2000. ‒ No. 217. ‒ pp. 721-729.
26. Joubert, K.E. The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days / K.E. Joubert // J. S. Afr. Vet. Assoc. ‒ 2009. ‒ Vol. 80. ‒ No. 3. ‒ pp.179-184.
27. Ko, J.C. Renal effects of carprofen administered to healthy dogs anesthetized with propofol and isoflurane / J.C Ko., T. Miyabiyashi, R.E. Mandsager, et al. // J Am Vet Med Assoc. ‒ 2000. ‒ No. 217. ‒ pp. 346-349.
28. Kondo, Y. Efficacy and safety of firocoxib for the treatment of pain associated with soft tissue surgery in dogs under field conditions in Japan / Y. Kondo, K Takashima., S. Matsumoto, et al. // J Vet Med Sci. ‒ 2012. ‒ No. 74(10). ‒ pp. 1283-1289. doihttps://doi.org/10.1292/jvms.11-0306.
29. KuKanich, B. Clinical pharmacology of nonsteroidal antiinflammatory drugs in dogs / B. KuKanich, T. Bidgood, O. Knesl // Vet Anaesth Analg, ‒ 2012. ‒ No. 39(1). ‒ pp. 69-90.
30. Lascelles, B.D. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003) / B.D. Lascelles, A.T. Blikslager, S.M. Fox, D. Reece // J Am Vet Med Assoc. ‒ 2005. ‒ No. 227(7). ‒ pp. 1112-1117. doihttps://doi.org/10.2460/javma.2005.227.1112.
31. Lees, P. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest / P. Lees, M.F. Landoni, J. Giraudel, P.L. Toutain // Journal of Veterinary Pharmacology and Therapeutics. ‒ 2004. ‒ No. 27, ‒ pp. 479-490.
32. Little, D. Cyclooxygenase (COX) inhibitors and the intestine / D. Little, S.L. Jones, A.T. Blikslager // Journal of Veterinary Internal Medicine. ‒ 2007. ‒ No. 21(3), ‒ pp. 367-77.
33. Luna, S.P.L. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs / S.P.L. Luna, A.C. Basilio, P.V.M Steagall, et al. // Am J Vet Res. ‒ 2007. ‒ No. 68. ‒ pp. 258-264.
34. MacPhail, C.M. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs / C.M. MacPhail, M.R. Lappin, D.J. Meyer, S.G. Smith, C.R.L. Webster, P.J. Armstrong // Journal of the American Veterinary Medical Association. ‒ 1998. ‒ No. 212(12). ‒ pp. 1895-901.
35. McCann, M.E. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis / M.E. McCann, R. Donald, D Zhang., C. Brideau, W.C. Black, P.D. Hanson, et al. // American Journal of Veterinary Research. ‒ 2004. ‒ No. 65(4). ‒ pp. 503-12.
36. Millis, D.L. The effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs / D.L. Millis, J.P Weigel., T. Moyers, et al. // Vet Ther. ‒ 2002. ‒ No. 3. ‒ pp. 453-464.
37. Monteiro-Steagall, B.P. Systematic Review of NSAIDs-Induced Adverse Effects in Dogs / B.P. Monteiro-Steagall, P.V.M Steagall., B.D.X. Lascelles // J. Vet Inter. Med. ‒ 2013. ‒ Vol. 27. ‒ Iss. 5. ‒ pp. 1011-1019.
38. Murrell, J. Firocoxib / J. Murrell // Companion Animal. ‒ 2009. ‒ No. 14 (3). ‒ pp. 47-49.
39. Nakagawa, K. Hepatocellular toxicosis associated with the alternate administration of carprofen and meloxicam in a Siberian Husky / K. Nakagawa, T. Yamagami, N. Takemura // Journal of Veterinary Medical Science. ‒ 2005. ‒ No. 67(10). ‒ pp. 1051-3.
40. National Competent Authorities for the implementation of Directive 2010/63/EU on the protection of animals used for scientific purposes. Working document on a severity assessment framework. Brussels, 11–12 July 2012;
41. Papich, M.G. An update on nonsteroidal anti – inflammatory drugs (NSAIDs) in small animals / M.G. Papich // Vet Clin Small Anim. ‒ 2008. ‒ No. 38. ‒ pp. 1243-1266.
42. Pettitt, R.A. Investigation and management of canine osteoarthritis / R.A. Pettitt, A.J. German // In Pract. ‒ 2015 Nov. ‒ Vol. 11. ‒ No. 37(Suppl 1). ‒ pp. 1-8.
43. Pollmeier, M. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis / M. Pollmeier, C. Toulemonde, C. Fleishman, P.D. Hanson // Vet Rec. ‒ 2006. ‒ No. 159(17). ‒ pp. 547-51.
44. Price, T., Molecular and Cell Biology of Pain / T. Price, G. Dussor. 1st Edition. Academic Press, 2015. ‒ 648 r.
45. Roitner, M. Prevalence of osteoarthritis in the shoulder, elbow, hip and stifle joints of dogs older than 8 years / J. Klever, S. Reese, A. Meyer-Lindenberg // Vet J. ‒ 2024. ‒ No. 305. ‒ pp. 106132. doihttps://doi.org/10.1016/j.tvjl.2024.106132.
46. Ryan, W.G. Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study / W.G. Ryan, K. Moldave, D. Carithers // Vet Ther. ‒ 2006. ‒ No. 7(2). ‒ pp. 119-126.
47. Smith, G.K. Pathogenesis, diagnosis, and control of canine hip dysplasia / G.K. Smith, G.T. Karbe, K.A. Agnello, et al. In: Tobias KM, Johnston SA, editors. Veterinary surgery small animal. St Louis (MO): Elsevier Saunders; 2012. ‒ pp. 824-48.
48. Steagall, P.V. Evaluation of the adverse effects of oral firocoxib in healthy dogs / P.V. Steagall, F.B. Mantovani, T.H. Ferreira, E.S. Salcedo, F.Q. Moutinho, S.P. Luna // J Vet Pharmacol Ther. ‒ 2007. ‒ No. 30(3). ‒ pp. 218-223. doihttps://doi.org/10.1111/j.1365-2885.2007.00842.x.
49. Wilson, J.E. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs / J.E. Wilson, N.V. Chandrasekharan, K.D. Westover, K.B. Eager, D.L. Simmons // American Journal of Veterinary Research. ‒ 2004. ‒ No. 65(6). ‒ pp. 810-8.
